February 12, 2014: Ibrutinib (Imbruvica) receives accelerated approval for patients with chronic lymphocytic leukemia who have received at least one prior therapy. 

January 10, 2014: Trametinib (Mekinist) and dabrafenib ­(Tafinlar) receive approval for use in combination in the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.